2025Year9Month22Day,Medtronic (New York Stock Exchange code:MDT) announced support for its adaptive use in personalized Parkinson's treatmentDBSThe research results of the algorithm,The result was published by the researchers in the Journal of the American Medical Association (JAMA) Journal of Neurology.This trial is conducted by Medtronic for patients with Parkinson's disease.BrainSenseAdaptive Deep Brain Stimulation (aDBS) The first evaluation.

Medtronic, as one of the largest medical technology companies globally,2Monthly AcquisitionFDAApprovalBrainSense aDBS, achieving an important milestone, and the study also receivedBrainSenseTheCELogo Approval.Medtronic claims this is the world's first closed-loop system for Parkinson's patients.DBSSystem.

BrainSense aDBSThrough MedtronicPerceptNeurostimulators provide real-time, adaptive therapy, dynamically adjusting stimulation based on each individual's unique brain activity in clinical settings or daily life.BrainSense EITechnology can be improvedDBSProgramming to ensure optimal initial contact selection in a shorter time. ThisExternally,Medtronic will also focus on brain-computer interfaces (BCI) Technology IntegrationDBSTherapy, aimed at advancing the prevention, detection, diagnosis, rehabilitation, and recovery of complex neurological diseases.

Medtronic has designedADAPT - PDTest, for evaluationaDBSContinuousDBS（cDBS) compared in terms of safety and effectiveness, secondary evaluations such as energy usage and patient preference were also conducted. Medtronic stated that, traditionallycDBSThe system, while able to improve the motor function of Parkinson's patients, cannot adapt in real-time to fluctuations in symptoms.ADAPT - PDAs the largest and longest study of its kind, it emphasizesaDBSRelative to the potential of traditional methods, stability was previously confirmed.cDBSAnd the clinical efficacy of drug treatment in patients.The study shows that, compared withcDBSIn comparison,aDBSSafe, well-tolerated, and an effective treatment method.

This study evaluated two modes: single-threshold and dual-threshold.aDBSAlgorithm, Observation45Number of Patients Exceeded30Days, including40Number of patients receivedaDBSMore than a year. The study met its primary efficacy endpoint, with the majority of patients...aDBSAndcDBSThe "on" time was comparable during the period, with no troublesome dyskinesia. Medtronic conducted this research globally, with participants from the United States, Canada, and Europe.10Center registration.

Medtronic Senior Distinguished Engineer,BrainSenseOne of the inventors of the technologyScott StanslaskiThe comment stated,This studyThis is another milestone for the Parkinson's disease community and the field of neuromodulation. Adaptive deep brain stimulation has the potential to personalize care in new ways, and this study provides compelling clinical evidence. These results validate more than a decade of development, collaboration with Parkinson's disease experts, and perseverance, further enhancing...aDBSAs the confidence in the development of the next generation of treatments for Parkinson's disease patients. He also stated that this innovation began with the utilization of proprietaryBrainSenseTechnology collaborates with globally leading Parkinson's disease experts to develop a complete, sensor-supported solution.DBSSystem, this development also positions Medtronic at the forefront of therapeutic brain-computer interfaces (BCI) Technology incorporatedDBSAt the forefront of treatment, aiming to advance progress in complex neurological disorders.